SARS-CoV-2 Nucleocapsid Protein Increases RANTES Levels in Glioblastoma Cells

Medical News: Understanding the Impact of SARS-CoV-2 on Brain Cells
The SARS-CoV-2 virus, responsible for the COVID-19 pandemic, has been extensively studied for its effects on lung tissues and systemic inflammation. However, recent research sheds light on its impact on the brain, specifically glioblastoma cells. A team of scientists from the Biology Department, School of Sciences and Humanities at Nazarbayev University in Kazakhstan has investigated how the nucleocapsid (N) protein of the virus influences cytokine levels in brain cells. Their findings suggest a significant increase in the expression of RANTES, a chemokine involved in immune responses.


SARS-CoV-2 Nucleocapsid Protein Increases RANTES Levels in Glioblastoma Cells

This Medical News report focuses on how the SARS-CoV-2 N protein affects glioblastoma cells, a type of brain cancer cell line. The research highlights a potential link between COVID-19 and neurological inflammation, which could have broader implications for long-term neurological symptoms in infected individuals.
 
The Role of the Nucleocapsid Protein in Cytokine Production
The SARS-CoV-2 virus contains several structural proteins, including the N protein, which plays a crucial role in viral replication and RNA packaging. Previous studies have shown that the N protein triggers the release of inflammatory cytokines, particularly interleukin-6 (IL-6), in lung cells, monocytes, and macrophages. However, its impact on brain cells has remained largely unexplored.
 
The researchers aimed to determine whether the N protein would induce a similar inflammatory response in glioblastoma cells. Using A172 and U87 glioblastoma cell lines, they treated the cells with recombinant SARS-CoV-2 N protein and monitored cytokine levels over 48 hours.
 
Key Study Findings
One of the most striking discoveries was the upregulation of RANTES (Regulated upon Activation, Normal T Cell Expressed and Secreted) in A172 glioblastoma cells following exposure to the N protein. This upregulation was observed at both the mRNA and protein levels, indicating a strong cellular response to the viral protein. Surprisingly, IL-6, which is commonly associated with COVID-19 inflammation, was not significantly affected in these cells.
 
To further validate their findings, the researchers conducted real-time quantitative PCR (RT-qPCR) analysis, which confirmed a 29.2-fold increase in RANTES expression in A172 cells. This result suggests that the N protein may selectively activate certain cytokines in different cell types, potentially leading to unique inflammatory responses in brain tissues.
 
Interestingly, the same effect was not observed in U87 glioblastoma cells, highlighting a cell-specific response to the N protein. This variation in cytokine expression between different glioblastoma cell lines underscores the complexity of viral-host interactions and suggests that the effects of SARS-CoV-2 may vary across different brain cell types.
 
No Impact on Cell Viability or Migrat ion
Despite the increase in RANTES levels, the study found no evidence that the N protein affected the viability or migration of glioblastoma cells. Using propidium iodide staining and flow cytometry, the researchers confirmed that cell viability remained unchanged after N protein treatment. Additionally, a wound healing assay showed no significant differences in cell migration between treated and untreated groups.
 
These findings indicate that while the N protein can modulate cytokine expression, it does not appear to directly influence glioblastoma cell survival or movement. This suggests that the primary impact of the N protein on brain cells may be related to immune signaling rather than direct cytotoxicity.
 
Potential Implications for Neurological Symptoms in COVID-19
The upregulation of RANTES in glioblastoma cells raises important questions about the neurological effects of SARS-CoV-2 infection. RANTES is known to play a role in recruiting immune cells to sites of inflammation and has been implicated in various neuroinflammatory conditions. Increased levels of this chemokine could contribute to the neurological symptoms observed in some COVID-19 patients, such as headaches, cognitive impairment, and anosmia (loss of smell).
 
Previous studies have suggested that SARS-CoV-2 can enter the central nervous system (CNS) through the olfactory nerve, leading to viral presence in brain tissues. The findings of this study support the idea that viral proteins, even in the absence of direct viral infection, can trigger inflammatory responses in brain cells. This could help explain why some COVID-19 patients experience lingering neurological issues even after recovering from the acute phase of the disease.
 
The Link Between RANTES and COVID-19 Severity
Other research has shown that RANTES levels are significantly elevated in critically ill COVID-19 patients. Some studies suggest that blocking the RANTES receptor (CCR5) with monoclonal antibodies can reduce inflammation and improve outcomes in severe cases. However, conflicting evidence indicates that higher RANTES levels may also be associated with lower mortality in certain patient populations.
 
This dual role of RANTES in COVID-19 highlights the need for further research to determine whether its upregulation in glioblastoma cells is beneficial or harmful. Understanding the precise mechanisms by which the N protein influences cytokine production in different tissues could pave the way for targeted therapeutic strategies to mitigate inflammation-related complications of COVID-19.
 
Conclusion
This study provides valuable insights into how the SARS-CoV-2 N protein modulates cytokine expression in brain cells. The key finding that RANTES is significantly upregulated in A172 glioblastoma cells suggests a potential mechanism for COVID-19-related neurological inflammation. However, the lack of effect on cell viability and migration indicates that the N protein does not directly harm glioblastoma cells but may instead alter immune signaling pathways.
 
Further research is needed to determine whether similar effects occur in primary brain cells, such as astrocytes and microglia, which play crucial roles in neuroinflammation. Additionally, understanding how different variants of SARS-CoV-2 impact cytokine production in the brain could help predict long-term neurological consequences of infection.
 
The study findings were published in the peer-reviewed journal: Molecules.
https://www.mdpi.com/1420-3049/30/5/1066
 
For the latest COVID-19 News, keep on logging to Thailand Medical News.
 
Read Also:
https://www.thailandmedical.news/news/covid-19-and-glioblastoma-onset
 
https://www.thailandmedical.news/news/doctors-warn-of-rising-cases-of-glioblastoma-multiforme-in-the-united-states
 
https://www.thailandmedical.news/news/breaking-texas-md-anderson-study-finds-that-covid-19-accelerates-brain-tumor-progression-and-possibly-causes-new-onset-glioblastomas

https://www.thailandmedical.news/pages/thailand_doctors_listings